One-time treatment with the gene therapy FLT201 (avigbagene parvec) may help control Gaucher disease without the need for additional therapies, according to new data from four patients in an early clinical trial. Spur Therapeutics, the company developing FLT201, presented the data at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress, held […] The post One-time gene therapy controls Gaucher disease symptoms appeared first on Gaucher Disease News.
